Catherine Eckford2025-12-01T14:44:27
If approved in Europe, atogepant would provide patients with a new acute treatment option for migraine attacks.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-30T10:37:00Z
Sponsored by Bruker (SciY), European Pharmaceutical Review
2026-06-29T06:00:00Z
Sponsored by Lubrizol Advanced Materials Europe BV
2026-06-22T13:25:00Z
Sponsored by IMA Pharma
2026-06-29T06:00:00
Sponsored by Lubrizol Advanced Materials Europe BV
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-03-27T15:37:00
Sponsored by IMA Pharma
2025-11-05T15:00:00
Sponsored by FUJIFILM Wako Chemicals Europe GmbH
2026-06-10T15:00:00
Sponsored by BioDuro
2026-04-29T14:00:00
Sponsored by USP
Site powered by Webvision Cloud